Tags Archive Navigation
icon
-
Media ReleaseNovartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Media ReleaseInternational research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
-
Media ReleaseNovartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities
-
Media ReleaseNovartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
-
Media ReleaseNovartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
-
Media ReleaseNovartis expands Africa Sickle Cell Disease program to Uganda and Tanzania
-
Media ReleaseNovartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
-
Media ReleaseSandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe
-
Media ReleaseNovartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
-
Media ReleaseNew collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- › Next page